Newcomb P B, Stone W D, Richardson P C, Smith P M, Gent A, Donovan B
Practitioner. 1976 Sep;217(1299):435-8.
Forty-five patients with chronic gastric ulcers were treated as out-patients in a double-blind comparison of gefarnate (geranyl farnesylacetate), 50 mg four times daily, with the same number of dummy capsules daily for five weeks. The mean percentage reduction in ulcer size assessed by radiography was 70-4 per cent in the gefarnate patients compared with 27-8 per cent in those receiving placebo capsules. This difference is statistically significant (p less than 0-05, with a two-tailed test). No change in the electrolyte balance occurred in any of the patients and no side-effects were reported. These results suggest that gefarnate promotes the healing of gastric ulcers in ambulant patients. Its apparent absence of side-effects makes it a safe ans useful drug.
45例慢性胃溃疡患者作为门诊病人，在一项双盲试验中接受治疗，比较了每天4次、每次50毫克的吉法酯（香叶基法呢酯）与每天服用相同数量的安慰剂胶囊，为期5周。通过X光检查评估，服用吉法酯的患者溃疡面积平均减少了70.4%，而服用安慰剂胶囊的患者为27.8%。这种差异具有统计学意义（双侧检验，p小于0.05）。所有患者的电解质平衡均未发生变化，也未报告有副作用。这些结果表明，吉法酯可促进门诊胃溃疡患者的溃疡愈合。其明显无副作用使其成为一种安全有效的药物。
